Dillon & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Dillon & Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,715	Closed	-$215K	–	79
2023 Q3	$215K	Sell	3,715 -75	-2%	-$4.59K	0.04%	76
2023 Q2	$243K	Sell	3,790 -15	-0.4%	-$1.01K	0.04%	74
2023 Q1	$263K	Hold	3,805	–	–	0.05%	72
2022 Q4	$274K	Sell	3,805 -150	-4%	-$11.3K	0.06%	67
2022 Q3	$281K	Hold	3,955	–	–	0.07%	64
2022 Q2	$305K	Hold	3,955	–	–	0.07%	62
2022 Q1	$289K	Hold	3,955	–	–	0.05%	63
2021 Q4	$245K	Sell	3,955 -463	-10%	-$27.2K	0.04%	69
2021 Q3	$261K	Sell	4,418 -9	-0.2%	-$593	0.05%	63
2021 Q2	$297K	Sell	4,427 -1,180	-21%	-$76.9K	0.06%	61
2021 Q1	$353K	Sell	5,607 -51	-0.9%	-$3.17K	0.08%	59
2020 Q4	$351K	Buy	5,658 +51	+0.9%	+$3.14K	0.08%	56
2020 Q3	$336K	Sell	5,607 -77	-1%	-$4.63K	0.08%	55
2020 Q2	$335K	Hold	5,684	–	–	0.09%	56
2020 Q1	$318K	Hold	5,684	–	–	0.11%	55
2019 Q4	$364K	Buy	+5,684	New	+$326K	0.1%	56
2019 Q1	–	Sell	-4,090	Closed	-$213K	–	67
2018 Q4	$213K	Sell	4,090 -1,150	-22%	-$61.8K	0.08%	62
2018 Q3	$325K	Sell	5,240 -515	-9%	-$30.6K	0.11%	59
2018 Q2	$317K	Buy	5,755 +1,000	+21%	+$54K	0.12%	59
2018 Q1	$300K	Sell	4,755 -10	-0.2%	-$643	0.12%	60
2017 Q4	$291K	Buy	4,765 +540	+13%	+$33.8K	0.11%	61
2017 Q3	$270K	Hold	4,225	–	–	0.11%	61
2017 Q2	$237K	Hold	4,225	–	–	0.1%	67
2017 Q1	$228K	Buy	4,225 +275	+7%	+$15.1K	0.1%	67
2016 Q4	$229K	Buy	+3,950	New	+$216K	0.1%	66

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dillon & Associates's BMY Position: Q4 2023 in Review

Dillon & Associates sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 3,715 shares — an estimated $215K sold.

Dillon & Associates first reported a position in BMY in Q4 2016 and held it in 25 quarters. The position peaked at $364K in Q4 2019. 2,364 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Dillon & Associates reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Dillon & Associates sold 3,715 Bristol-Myers Squibb shares in Q4 2023, an estimated $215K.
Dillon & Associates first reported a position in Bristol-Myers Squibb in Q4 2016 and held it in 25 quarters.
Dillon & Associates's Bristol-Myers Squibb position peaked at $364K in Q4 2019.
2,364 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Dillon & Associates's 13F filing for Q4 2023, filed 8 Feb 2024.